Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Multicenter, Randomized Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Korean Patients With Gastric Inflammation

NCT02386007 is registered in ClinicalTrials.gov with Daewon Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT02386007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02386007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Multicenter, Randomized Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Korean Patients With Gastric Inflammation
Lead sponsor
Daewon Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
Not reported
Completion date
Not reported
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute and chronic gastric inflammation patients